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Abstract 
Alcohol addiction and abuse is a main contributor to the global burden of disease and is a high public 
health priority. Alcohol addiction is a chronically relapsing neurobiological disorder affecting multiple 
neurotransmitter systems. Considerable evidence suggests that the mesolimbic dopamine system is 
the primary substrate for the acute rewarding and reinforcing effects of alcohol. Over time, excessive 
alcohol intake causes chronic functional changes in this system that may trigger off the transition 
from controlled recreational alcohol use to the compulsive intake that characterizes true addiction. 
Pharmacotherapy is emerging as a valuable tool for treatment of alcohol addiction, yet the current 
agents approved for this condition are only modestly effective and there is a need for improved 
treatments. It was recently revealed that extracellular glycine levels are important for regulating 
alcohol consumption and that the glycine receptor (GlyR) in nucleus accumbens (nAc) is an access 
point for alcohol to the mesolimbic dopamine system. The glycine transporter-1 protein (GlyT-1) is 
the main regulator of extracellular glycine concentrations and thus a key substrate for 
pharmacological manipulation of brain glycine levels. The aim of this thesis was to investigate (1) 
how modulation of extracellular glycine levels by inhibition of GlyT-1 affects the mesolimbic 
dopamine system, (2) how it interacts with alcohol-induced activation of mesolimbic dopamine, and 
(3) how GlyT-1 inhibition influences voluntary ethanol consumption. Effects on ethanol drinking were 
studied by using a limited access free-choice model in out-bred Wistar rats.  Effects on dopamine and 
glycine levels in nAc were examined by using in vivo brain microdialysis. First it was demonstrated 
that the GlyT-1 blocker Org25935 robustly and dose-dependently reduced voluntary ethanol intake 
and that the effect was reinstated after an alcohol withdrawal period. Next it was shown that 
Org25935 raised extracellular glycine levels by 87% in nAc, increased dopamine levels per se and 
most importantly prevented an ethanol-induced dopamine increase in nAc. It was then shown that 
the GlyR in nAc rather than the NMDA receptor is involved in mediating the effect of Org25935 on 
dopamine levels in nAc. The last study investigated the anti-alcohol drinking profile of another 
selective GlyT-1 inhibitor Org24598, and compared the effect to that of acamprosate.  In summary, 
the results propose that the GlyT-1 blocker Org25935 increases and stabilizes extracellular glycine 
levels which, via the GlyR, elevate and preserve a steady dopamine level, which in turn prevents 
additional ethanol-mediated GlyR activation and dopamine elevation. This adds to the growing 
evidence for the GlyR as an important player in the dopamine reward circuitry and in ethanol’s 
effects within this system. Two different GlyT-1 inhibitors demonstrated an excellent ability to 
decrease ethanol consumption in experimental animals. This thesis proposes that GlyT-1 inhibition 
may represent a new concept for treatment of alcohol addiction. 
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